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Reactive oxygen species (ROS) induced oxidative stress is believed to be a primary
causative factor of various inflammatory diseases. ROS has been linked with cancer, cor-
onary heart disease, and neurodegenerative diseases, and their presence in the body
causes damage to the DNA of cells. Antioxidants exert their effects by scavenging or
preventing the generation of ROS, which can protect the formation of free radicals and
retard the progress of many chronic diseases, including cancer, inflammation, and car-
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A series of novel 5-alkyl/aryl thiadiazole substituted
thiazolidin-4-ones were synthesized by a two-step pro-
cess. In the first step, 5-alkyl/aryl substituted 2-amino-
thiadiazoles were synthesized, which on reaction with
substituted aromatic aldehydes and thioglycolic acid in
the presence of dicyclohexylcarbodiimide afforded thia-
zolidin-4-ones. All the compounds were synthesized in
fairly good yields and their structures were confirmed
by spectral and physical data. The title compounds were
screened for in vitro anti-proliferative activity on human
breast adenocarcinoma cells (MCF-7) by MTT assay.
Most of the derivatives showed an IC50 less than 150
µmol L–1. Among the compounds tested, 2-(2-nitrophe-
nyl)-3-(5-methyl-1,3,4-thiadiazol-2-yl)-thiazolidin-4-one
(3f), 2-(3-fluorophenyl)-3-(5-methyl-1,3,4-thiadiazol-2-
-yl)-thiazolidin-4-one (3b), and 2-(4-chlorophenyl)-3-
-(5-methyl-1,3,4-thiadiazol-2-yl)-thiazolidin-4-one (3c)
were found to be the most active derivatives with IC50
values of 46.34, 66.84, and 60.71 µmol L–1, respectively.
Antioxidant studies of all the synthesized compounds
were carried out by diphenylpicrylhydrazyl (DPPH) as-
say. Among the compounds tested, 2-phenyl-3-(5-styryl-
-1,3,4-thiadiazol-2-yl)-thiazolidin-4-one (3s) elicited supe-
rior antioxidant activity with IC50 of 161.93 µmol L–1.
Keywords: thiadiazole, thiazolidin-4-ones, anticancer, an-
tioxidant
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diovascular diseases (1). Despite significant progress achieved in anticancer therapy,
high systemic toxicity and drug resistance remain a major challenge for contemporary
medicine in the management of cancers. Chemotherapy causes severe side-effects,
which may be due to its cytotoxic effect on normal cells. Therefore, it is important that
anticancer drugs display antiproliferative and cytotoxic activity in tumor cells without
affecting normal tissues. Taking all the above mentioned facts into account, the develop-
ment of novel antioxidant chemotherapeutics is being pursued.
Thiazolidin-4-one is a versatile scaffold for designing potential bioactive agents.
Thiazolidin-4-one derivatives have been reported for broad spectrum of biological activ-
ities such as antioxidant (2), anticancer (3, 4), anti-inflammatory (5, 6), antimicrobial (7,
8), anti-HIV (9, 10), antiviral (11), anticonvulsant (12, 13), and antihypertensive (14) ac-
tivities. Mechanisms of thiazolidin-4-one and related heterocycles for anticancer activity
may be associated with their affinity to anticancer biotargets, such as non-membrane
protein tyrosine phosphatase (SHP-2) (15), JNK-stimulating phosphatase-1 (JSP-1) (16)
tumor necrosis factor TNF-a (17), antiapoptotic biocomplex Bcl-XL-BH3 (18) and integrin
avb3 (19), etc. On the other hand, azoles are proven chemotherapeutic agents. Among
the azoles, 1,3,4-thiadiazole and its derivatives are well known for its in vitro and in vivo
anticancer activity (20, 21). The 1,3,4-thiadiazoles induce early-phase apoptosis in hu-
man non-small lung cancer A549 cells through down-regulation of Bcl-XL and up-regu-
lation of Bax expression (22). The 1,3,4-thiadiazoles also inhibit Akt/protein kinaze B
(PKB) of cancer cells (22). In addition, these compounds have also exhibited anti-angio-
genic activity in the nude mice angiogenesis model (22).
Since 1,3,4-thiadiazole and thiazolidin-4-one moieties are biologically proven anti-
cancer and antioxidant pharmacophores and substitution in these scaffolds may further
enhance their activity, prompted us to undertake this problem. Moreover, the combina-
tion of two pharmacophores in a single molecule is a well established hypothesis for
synthesis of more active drugs with dual activity (23). Also, single molecule acting on
multiple targets is better drug candidate compared to drug combinations, as administra-
tion of single drug will have more predictable pharmacokinetic and pharmacodynamic
properties and improved patient compliance (23). Thus, a series of novel 5-alkyl/aryl
thiadiazole substituted thiazolidine-4-ones were synthesized and evaluated for their an-
tioxidant and anticancer activity.
EXPERIMENTAL
Melting points were determined by using a melting point apparatus (Shital Scien-
tific Industries, India) and were not corrected. Infrared spectra were obtained on a Shi-
madzu FT-IR-8310 (Shimadzu, Japan) using potassium bromide discs. 1H NMR spectra
were recorded on a Bruker 400 MHz spectrometer (Bruker, Germany). Chemical shifts
are reported in parts per million (d) units relative to an internal standard of tetramethyl-
silane. Mass spectra were recorded on a GC-MS QP 5050 (Shimadzu). Microanalysis was
done on a Perkin-Elmer model 2400 CHN analyzer (USA). The purity of all compounds
was established by a single spot on TLC plates (Merck, Germany). Iodine vapour was
used as developing agent. The solvent system used for TLC was n-hexane/ ethyl acetate
(3:7).
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General procedure for synthesis of 2-amino-5-alkyl-1,3,4-thiadiazoles (2a,b)
Required fatty acid (0.15 mol), concentrated sulfuric acid (25 mL) and thiosemicar-
bazide (0.15 mol) were slowly heated to 80–90 °C on a thermostatically controlled water
bath for 7 h. After cooling the contents were poured onto crushed ice. The acid was neu-
tralized with 10 % ammonia solution. The crude precipitate which separated was filte-
red and washed several times with distilled water and dried. Final product was recry-
stallized from hot water (24).
General procedure for synthesis of 2-amino-5-aryl-1,3,4-thiadiazoles (2c-m)
Aromatic aldehyde (0.2 mol) in warm alcohol (300 mL) was added to a solution of
thiosemicarbazide (0.2 mol) in hot water (300 mL). It was mixed slowly with continuous
stirring. The product separated was filtered off and recrystallized from 50 % aqueous
ethanol. Thiosemicarbazone (0.005 mol) obtained was suspended in 300 mL distilled wa-
ter in a 1000 mL beaker. Ferric chloride solution (0.15 mol in 300 mL distilled water) was
added to it. The contents were heated and maintained at 80–90 °C for 1 h, then it was fil-
tered hot. A mixture of citric acid (0.11 mol) and sodium citrate (0.05 mol) was added to
the filtrate and stirred. After cooling, the whole solution was taken in a bigger vessel (to
account for the increase in volume) and neutralized with 10 % aqueous ammonia. The
precipitate separated out was filtered and recrystallized from 25 % aqueous ethanol (24).
General procedure for synthesis of 2-aryl-3-(5-alkyl/aryl-1,3,4-thiadiazol-2-yl)-
-thiazolidin-4-ones (3a-s)
A mixture of appropriate heterocyclic amine (1.0 mmol), i.e. synthesized thiadiazole
derivatives (2a-m) and aromatic aldehyde (2.0 mmol) were stirred in tetrahydrofuran
under ice-cold conditions for 5 min, followed by the addition of thioglycolic acid (3.0
mmol). After 5 min, dicyclohexylcarbodiimide (DCC) (1.2 mmol) was added to the reac-
tion mixture at 0 °C and the reaction mixture was stirred for additional 50 min at room
temperature to complete the reaction. The precipitated dicyclohexylurea was filtered off;
the filtrate was concentrated to dryness under reduced pressure. Deionized water was
added to the residue and the mixture was extracted with chloroform. The organic layer
was successively washed with 5 % aqueous sodium hydrogen carbonate and dried over
anhydrous sodium sulphate. The crude solid obtained on evaporation of the solvent un-
der reduced pressure was purified by column chromatography (n-hexane/ethyl acetate,
5:5) and further by recrystallization in methanol to yield a crystalline product (25).
In vitro antioxidant screening
Free radical scavenging capacity of test compounds was studied by diphenylpicryl-
hydrazyl (DPPH) scavenging assay (26). The assay was carried out in a 96-well micro-
titre plate. DPPH solution was prepared by dissolving 3.96 mg of DPPH in 50 mL of
methanol to give a concentration of 200 µmol L–1. Stock solution (5000 µg mL–1 in
DMSO) of test compounds was suitably diluted with DMSO to get final concentrations
of 1000, 500, 250, 125, 62.5, 31.25, 15.63, and 7.81 µg mL–1. Each test compound was ad-
ded to each well separately in triplicate. DPPH solution was added to each well of test
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compounds. Negative control wells were loaded with 100 mL of DMSO and 100 mL of
DPPH solution each. Sample blank (200 µL of test compound in 1000, 500, 250, 125, 62.5,
31.25, 15.63, and 7.81 µg mL–1 concentration, dissolved in DMSO, no DPPH added) and
control blank (200 µL of methanol without DPPH) were also performed. The plates were
incubated at 37 °C for 30 min without exposing to light and the absorbance of each solu-
tion was measured. Ascorbic acid was used as a reference compound. Results of antioxi-
dant assay are expressed as mean IC50 ± SEM (Table III).
In vitro anticancer activity in cultured cells by MTT assay
All the synthesized compounds were tested for in vitro anticancer activity against
human breast adenocarcinoma cells (MCF-7 cells) by the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay (27). Exponentially growing MCF-7
cells were harvested from a 75-cm2 tissue culture flask and a stock cell suspension (1x105
cell mL–1) was prepared. A 96-well flat bottom tissue culture plate was seeded with
2 x 103 cells in 0.1 mL of Eagle’s minimum essential medium (MEM medium) supple-
mented with 10 % fetal bovine serum (FBS) and allowed to attach for 24 h. After 24 h of
incubation cells were treated with 7.5, 15, 30, and 60 µg mL–1 of test compounds. The
cells in the control group received only the medium containing 0.2 % DMSO. Each treat-
ment was performed in triplicate. After the treatment for 48 h, drug containing medium
was removed and cells were washed with 200 µL of phosphate buffered saline (PBS). To
each well, 100 µL of MTT reagent (1 mg mL–1 MTT dissolved in MEM medium) was
added and incubated for 4 h at 37 °C. After 4 h of incubation the plate was inverted on
tissue paper to remove the MTT reagent. To solubilize formazan crystals in the wells,
100 µL of DMSO was added to each well. The optical density (absorbance) was mea-
sured and percentage inhibition or percentage cell death was calculated. Cisplatin was




Thiadiazole substituted thiazolidin-4-one derivatives were synthesized by two-step
process. In the step one, 2-amino-5-aryl/alkyl-1,3,4-thiadiazoles (2a-m) were synthesi-
zed (Scheme 1), while in the step two, one pot reaction of 2-amino-5-aryl/alkyl-1,3,4-
-thiadiazoles with different aryl aldehydes and thioglycolic acid in the presence of
dicyclohexylcarbodiimide afforded thiadiazole substituted thiazolidin-4-ones (3a-s)
(Scheme 1). In the initial step of reaction, amino group nitrogen attacks the carbonyl car-
bon of aldehyde function and forms imine. Then thiol nucleophile attacks the imine car-
bon followed by intramolecular cyclization with loss of water resulting in the formation
of thiazolidin-4-one. The last step is crucial for the high yield of thiazolidin-4-ones. The
dehydrating agent DCC accelerates the intramolecular cyclization process and increases
the yield of the reaction as well.
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Spectral data of synthesized compounds (Table II) along with physical and analyti-
cal data (Table I) confirmed the successful synthesis of thiadiazole substituted thiazo-
lidin-4-ones (3a-s). The FT-IR (KBr pellet) spectra of compounds exhibited peaks corre-
sponding to C=O and C=N functions. IR spectra of all thiadiazole substituted thiazo-
lidin-4-ones showed C=N stretching between 1605 and 1634 cm–1. The carbonyl group of
synthesized compounds appeared at 1671–1700 cm–1. Proton NMR spectra of all the syn-
thesized compounds exhibited double doublet peaks between 3.84 and 4.34 ppm (J =
15.6–16.4 Hz) corresponding to two methylene protons (5-HA and 5-HB) of the thiazo-
lidin-4-one moiety, which confirms the formation of thiazolidinone ring. The 5-HA pro-
ton appeared more downfield than the 5-HB proton due to its proximity to the 4-one
(ketonic) group. The methine (–C-H–) proton of cyclized thiazolidin-4-one moiety ap-
peared as a singlet between 6.69–6.99 ppm. Methyl group present in the compounds
(3a-g) appeared as singlet between 1.26–1.31 ppm. Aromatic protons of all synthesized
compounds appeared between 7.20 and 7.98 ppm. Mass spectra of all compounds sho-
wed corresponding molecular ion (M+) peaks in addition to the characteristic fragmen-
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tation peaks. Chloro and bromo substituted compounds displayed M+2 peaks in addi-
tion to the molecular ion peaks (M+). Compounds possessing chloro group exhibited M+
to M+2 peak height ratio of 3:1, while bromo group possessing compounds showed M+
to M+2 peak height ratio of 1:1. Most compounds showed notable peaks at m/z 104 and
77 for molecular ions C6H5CN+ and C6H5+, respectively.
In vitro antioxidant activity by DPPH assay
Among the compounds tested for antioxidant activity, 2-phenyl-3-(5-styryl-1,3,4-
-thiadiazol-2-yl)-thiazolidin-4-one (3s) exhibited the highest antioxidant activity with the
IC50 value of 161.93 µmol L–1, while IC50 of reference compound ascorbic acid was found
to be 22.99 µmol L–1. Other moderately active compounds, 2-(2-bromophenyl)-3-(5-
methyl-1,3,4-thiadiazol-2-yl)-thiazolidin-4-one (3d) and 2-(2-nitrophenyl)-3-(5-methyl-
1,3,4-thiadiazol-2-yl)-thiazolidin-4-one (3f) showed the IC50 values of 254.67 and 252.05
µmol L–1, respectively. Substitution of styryl ring at 5th position of 1,3,4-thiadiazol-2-yl
moiety imparted maximum activity (3s), while, replacement of styryl ring with phenyl
ring (3i), substituted phenyl ring (3j-r) or methyl group (3a-h) resulted in the loss of ac-
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Elemental analysis calcd./found (%)
C H N
3a C12H11N3OS2 (277.03) 190–192 52 51.96/51.80 4.00/4.05 15.15/15.14
3b C12H10FN3OS2 (295.02) 140–142 45 48.80/48.54 3.41/3.38 14.23/14.32
3c C12H10ClN3OS2 (311.81) 180–183 43 46.22/46.00 3.23/3.35 13.48/13.55
3d C12H10BrN3OS2 (356.26) 180–181 40 40.46/40.75 2.83/2.68 11.79/11.85
3e C12H10BrN3OS2 (356.26) 179–181 52 40.46/40.80 2.83/2.74 11.79/11.95
3f C12H10N4O3S2 (322.36) 150–151 52 44.71/45.05 3.13/3.42 17.38/17.65
3g C12H10N4O3S2 (322.36) 160–163 54 44.71/44.98 3.13/3.45 17.38/17.25
3h C13H13N3OS2 (291.39) 184–185 66 53.58/53.95 4.50/4.89 14.42/14.21
3i C17H13N3OS2 (339.43) 182–183 55 60.15/59.91 3.86/3.75 12.38/12.15
3j C17H12FN3OS2 (357.43) 220–222 61 57.13/56.85 3.38/3.12 11.76/11.97
3k C17H12FN3OS2 (357.43) 190–191 68 57.13/56.98 3.38/3.78 11.76/11.85
3l C17H12FN3OS2 (357.43) 200–202 72 57.13/57.45 3.38/3.65 11.76/11.45
3m C17H12ClN3OS2 (373.88) 175–176 64 54.61/54.96 3.24/3.38 11.24/11.46
3n C17H12ClN3OS2 (373.88) 178–179 56 54.61/54.75 3.24/3.54 11.24/11.74
3o C17H12BrN3OS2 (418.33) 160–161 66 48.81/49.05 2.89/2.99 10.04/10.18
3p C17H12BrN3OS2 (418.33) 168–170 64 48.81/48.98 2.89/2.75 10.04/10.29
3q C17H12N4O3S2 (384.43) 210–211 69 53.11/53.26 3.15/3.53 14.57/14.89
3r C18H15N3O2S2 (369.46) 190–193 57 58.52/58.94 4.09/4.25 11.37/11.58
3s C19H15N3OS2 (365.47) 200–201 64 62.44/62.15 4.14/4.15 11.50/11.59
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Table II. Spectral data of synthesised compounds
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1.25 (t, 3H, -CH3 side chain), 2.99 (q, 2H, -CH2 of
side chain), 4.03 (dd, 1H, 5-HB of thiazolidinone
ring), 4.29 (dd, 1H, 5-HA of thiazolidinone ring),











4.09 (dd, 1H, 5-HB of thiazolidinone ring),
4.32 (dd, 1H, 5-HA of thiazolidinone ring),
6.80 (s, 1H, -CH of thiazolidinone ring),










4.12 (dd, 1H, 5-HB of thiazolidinone ring),
4.34 (dd, 1H, 5-HA of thiazolidinone ring),
6.85 (s, 1H, -CH of thiazolidinone ring),




tivity. Presence of methyl group at 5th position of 1,3,4-thiadiazol-2-yl moiety with
2-bromo (3d) or 2-nitro (3f) substituted phenyl ring at 2nd position of thiazolidin-4-one
moiety imparted moderate activity, while, fluoro, chloro, and ethyl substitutions (3b, 3c,
and 3h, respectively) on the phenyl ring of thiazolidin-4-one scaffold were inactive or
decreased the activity. Hence, it can be concluded that styryl substituted 1,3,4-thiadia-
zol-2-yl moiety with no substitution on 2-phenyl ring of thiazolidin-4-one moiety (3s)
was the most optimum substitution condition for antioxidant activity.
404







3.92 (dd, 1H, 5-HB of thiazolidinone ring),
4.15 (dd, 1H, 5-HA of thiazolidinone ring),
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4.29 (dd, 1H, 5-HA of thiazolidinone ring),
6.81 (s, 1H, -CH of thiazolidinone ring),









3.85 (dd, 1H, 5-HB of thiazolidinone ring),
3.98 (dd, 1H, 5-HA of thiazolidinone ring),
6.70 (s, 1H, -CH of thiazolidinone ring),











3.89 (dd, 1H, 5-HB of thiazolidinone ring),
4.17 (dd, 1H, 5-HA of thiazolidinone ring),
6.71 (s, 1H, -CH of thiazolidinone ring),











3.95 (dd, 1H, 5-HB of thiazolidinone ring),
4.27 (dd, 1H, 5-HA of thiazolidinone ring),
6.82 (s, 1H, -CH of thiazolidinone ring),










3.91 (dd, 1H, 5-HB of thiazolidinone ring),
4.14 (dd, 1H, 5-HA of thiazolidinone ring),
6.78 (s, 1H, -CH of thiazolidinone ring),










3.86 (dd, 1H, 5-HB of thiazolidinone ring),
4.03 (dd, 1H, 5-HA of thiazolidinone ring),
6.85 (s, 1H, -CH of thiazolidinone ring),










3.75 (s, 3H, -OCH3), 4.12 (dd, 1H, 5-HB of
thiazolidinone ring), 4.33 (dd, 1H, 5-HA of
thiazolidinone ring), 6.99 (s, 1H, -CH of









4.05 (dd, 1H, 5-HB of thiazolidinone ring), 4.24
(dd, 1H, 5-HA of thiazolidinone ring), 6.56 (d, 2H,
CH=CH), 6.90 (s, 1H, -CH of thiazolidinone ring),




In vitro anticancer activity by MTT assay
Anticancer assay results showed that compounds 2-(3-fluorophenyl)-3-(5-methyl-
1,3,4-thiadiazol-2-yl)-thiazolidin-4-one (3b), 2-(4-chlorophenyl)-3-(5-methyl-1,3,4-thia-
diazol-2-yl)-thiazolidin-4-one (3c), and 2-(2-nitrophenyl)-3-(5-methyl-1,3,4-thiadiazol-2-
yl)-thiazolidin-4-one (3f) were the most potent cytotoxic agents with IC50 values of 66.84,
60.71, and 46.34 µmol L–1, respectively. IC50 of reference drug cisplatin was found to be





zol-2-yl)-thiazolidin-4-ones (3p), and 2-phenyl-3-(5-styryl-1,3,4-thiadiazol-2-yl)-thiazoli-
din-4-ones (3s). It was observed that presence of 3-fluoro (3b), 4-chloro (3c), and 2-nitro
groups (3f) at phenyl ring of thiazolidin-4-one moiety confer maximum activity, while
bromo substitutions on phenyl ring (3d, 3e) resulted into the decreased activity. Also, re-
moval of halogen atoms at 2-phenyl ring (3a) or incorporation of ethyl group at 2-phenyl
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Table III. Antioxidant activity of synthesised
compounds





3d 254.67 ± 2.6
3e 337.17 ± 3.4
3f 252.05 ± 3.2
3g 336.46 ± 2.6
3h 532.28 ± 4.5
3i 461.57 ± 4.1
3j 401.34 ± 2.7
3k 389.42 ± 2.8
3l 336.29 ± 3.1
3m 345.51 ± 3.2
3n 351.15 ± 3.7
3o 336.29 ± 3.4
3p 413.17 ± 3.0
3q > 600
3r 350.09 ± 3.9
3s 161.93 ± 2.0
Ascorbic acid 22.99 ± 0.18
a IC50 – 50 % inhibitory concentration. Mean ± SEM,
n = 3.
Table IV. Cytotoxic activity of synthesized
compounds
Compd. IC50 (µmol L
–1)a
3a 173.88 ± 0.18
3b 66.84 ± 0.13
3c 60.71 ± 0.26
3d 89.04 ± 0.11
3e 100.18 ± 0.11
3f 46.34 ± 0.15
3g 76.99 ± 0.09
3h 142.08 ± 0.24
3i 150.55 ± 0.23
3j 88.77 ± 3.07
3k 154.66 ± 0.11
3l 144.61 ± 0.25
3m 158.15 ± 0.16
3n 81.15 ± 0.13
3o 100.45 ± 0.07
3p 77.50 ± 2.80
3q 104.93 ± 3.17
3r 134.06 ± 0.22
3s 94.21 ± 0.14
Cisplatin 10.56 ± 0.10
a IC50 – 50 % inhibitory concentration. Mean ± SEM,
n = 3.
ring (3h) caused further loss of activity. The styryl ring (3s) and halogen substituted phe-
nyl ring (3j, 3n, and 3p) at the 5th position of 1,3,4-thiadiazol-2-yl moiety exhibited
fairly good anticancer activity. Phenyl (3i) or 2-methoxyphenyl (3r) groups at the 5th po-
sition of 1,3,4-thiadiazol-2-yl moiety were found to be inactive. Structure activity rela-
tionship (SAR) study revealed that 3-fluorophenyl, 4-chlorophenyl, and 2-nitrophenyl
substitutions at the 2nd position of thiazolidin-4-one ring (3b, 3c, and 3f, respectively)
were more favorable than substitutions at the 5th position of 1,3,4-thiadiazol-2-yl moiety
(3i-s) for imparting anticancer activity.
CONCLUSIONS
Test compound 2-phenyl-3-(5-styryl-1,3,4-thiadiazol-2-yl)-thiazolidin-4-one (3s) was
found to be the most potent antioxidant with the IC50 value of 161.93 µmol L–1. The pre-
sence of styryl ring at thiadiazol-2-yl moiety was critical for the antioxidant property. In
the in vitro anticancer activity, most of the compounds exhibited IC50 values below 150
µM. The SAR study of tested compounds revealed that substitution of 3-fluorophenyl
(3b), 4-chlorophenyl (3c), and 2-nitrophenyl (3f) at the 2nd position of thiazolidin-4-one
moiety produced the most potent cytotoxic agents that exhibited IC50 below 70 µmol L–1
(3b, 3c, and 3f). Cytotoxic potential of (2-(3-fluorophenyl)-3-(5-methyl-1,3,4-thiadiazol-
-2-yl)-thiazolidin-4-one (3b), 2-(4-chlorophenyl)-3-(5-methyl-1,3,4-thiadiazol-2-yl)-thia-
zolidin-4-one (3c) and 2-(2-nitrophenyl)-3-(5-methyl-1,3,4-thiadiazol-2-yl)-thiazolidin-4-
one (3f) was comparable to that of the clinically used anticancer drug cisplatin. Further
modification in thiadiazole and thiazolidin-4-one scaffolds with intramolecular rearran-
gement of styryl, nitro and halogen groups on the both moieties and introduction of new
substituents preferably containing styryl, nitro, and halogen groups may give potent
thiadiazole substituted thiazolidin-4-ones.
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